- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06252584
Vaccination multipeptidique avec adjuvant XS15 chez les patients atteints de leucémie myéloïde aiguë (AML-VAC-XS15)
Vaccination multipeptidique avec adjuvant avec le ligand TLR1/2 XS15 chez les patients atteints de leucémie myéloïde aiguë (LAM) qui ont obtenu une rémission complète avec un traitement de première intention
The aim of this Phase I study is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a multi-peptide vaccine adjuvanted with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG (AML-VAC-XS15) in AML patients who have achieved CR or CRi with first line treatment.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Peptide vaccine: Multi-peptide vaccine cocktail comprising 9 different immunopeptidome-defined mutated and non-mutated AML/ leukemia stem and progenitor cell (LSC)-associated HLA class I and HLA class II peptides.
The vaccine cocktail is synthesized and formulated in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen (headed by Juliane Walz).
Treatment schedule:
The vaccine cocktail will be administered subcutaneously (s.c.) together with the (toll-like receptor )TLR1/2 ligand XS15 (50 µg) emulsified in Montanide ISA 51 VG (1:1) as adjuvant.
Two vaccinations within a 6-week interval are planned, with the option of one additional booster in case of insufficient response after the first two vaccinations.
Peptide vaccination will take place in AML patients that have achieved a morphological complete remission (CR) or a complete remission with incomplete blood count recovery (CRi) with standard first line treatment. Minimal residual disease (MRD) positivity is permitted.
Vaccination will start 4-28 weeks after last application of intensive chemotherapy). Any maintenance treatment, e.g. with oral azacytidine or midostaurin, or ongoing low intensity therapy, e.g. with HMA, venetoclax etc. is permitted, can be applied throughout the vaccination and continued after study treatment according to the treating physician's decision.
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Juliane Walz, Prof. Dr.
- Numéro de téléphone: 83275 +49 7071 29
- E-mail: kketi@med.uni-tuebingen.de
Sauvegarde des contacts de l'étude
- Nom: Helmut Salih, Prof.Dr.
- Numéro de téléphone: 83275 +49 7071 29
- E-mail: kketi@med.uni-tuebingen.de
Lieux d'étude
-
-
Baden-Wurttemberg
-
Tübingen, Baden-Wurttemberg, Allemagne, 72076
- Recrutement
- University Hospital Tuebingen
-
Contact:
- Juliane Walz, Prof. Dr.
- Numéro de téléphone: +49 07071 29 87305
- E-mail: kketi@med.uni-tuebingen.de
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Males or females aged ≥18 years of age
-
Existence of a written informed consent
-
Documented diagnosis of AML according to WHO guidelines
- morphological complete remission (CR) or complete remission with incomplete blood count recovery (CRi)
- positive MRD is permitted
- completion of previous intensive therapy (first vaccination 4-28 weeks after last application of chemotherapy) or
- ongoing low intensity treatment with e.g. hypomethylating agents (HMA), venetoclax, etc.
- ongoing maintenance treatment with e.g. oral azacytidine or midostaurin is permitted.
- not eligible for allogeneic stem cell transplantation
-
Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2
-
Adequate organ function laboratory values.
- bilirubin ≤ 3 times upper limit range (exception isolated indirect hyperbilirubinemia (Morbus Gilbert-Meulengracht)).
- alanine aminotransferase (ALT) and aminotransferase (AST), ≤ 5 times upper limit range
- creatinine clearance GFR > 30 ml/min (CKD-EPI)
- platelets > 50.000/μl
- absolute CD3+ T cell count ≥ 200/μl
-
negative serological hepatitis B test or negative PCR in case of positive serological test without evidence of an active infection, negative testing of hepatitis C RNA, negative HIV test within 6 weeks prior to study inclusion
-
Female patients of child bearing potential (FCBP) and male patients with partners of child bearing potential, who are sexually active, must agree to the use of two effective forms (at least one highly effective method) of contraception (for more detailed information see chapter 5.7 Contraception, pregnancy, sperm donation and nursing). This should be started from the signing of the informed consent and be continued until 3 months (both female and male patients) after last vaccination).
-
For FCBP two negative pregnancy tests (sensitivity of at least 25 mlU/mL) prior to first application of first vaccination, one at screening and the other prior (< 24 h) to first vaccination
-
Postmenopausal or evidence of non-child-bearing status
Exclusion Criteria:
-
Pregnant or breastfeeding.
-
Unwilling or unable to follow the study schedule for any reason.
-
Chemotherapy or other systemic therapy or radiotherapy, up to 14 days prior to the first dose of study drug (ongoing maintenance treatment or low intensity treatment is permitted).
-
Concurrent or previous treatment within 28 days in another interventional clinical trial with an investigational anticancer therapy or any other investigational therapy, which would interfere with the study's primary and secondary endpoints.
-
Major surgery within 28 days of dosing of study drug.
-
Treatment with immunotherapy agents within 28 days of dosing of study drug.
-
Diagnosis of acute promyelocytic leukemia (APL)
-
Autoimmune disease that requires or has required treatment with systemic immunosuppressive treatments, except low dose corticosteroids (< 10 mg/ day), in the past 1 year.
-
Prior history of malignancies, other than AML/myelodysplastic syndrome (MDS), unless the subject has been free of the disease for
≥ 2 years. Exceptions include the following: basal cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, histological finding of prostate cancer of TNM stage T1
-
Prior stem cell allograft or organ transplantation
-
Ongoing or active infection (including SARS-CoV-2)
-
Have received any live vaccination within 28 days prior to the first dose of AML-VAC-XS15.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Multipeptide Vaccination
The vaccine cocktail will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1) as adjuvant. Two vaccinations within a 6-week interval are planned, with the option of one additional booster in case of insufficient response after the first two vaccinations. Peptide vaccination will take place in AML patients that have achieved a morphological complete remission (CR) or a complete remission with incomplete blood count recovery (CRi) with standard first line treatment. MRD positivity is permitted. Vaccination will start 4-28 weeks after last application of intensive chemotherapy). Any maintenance treatment, e.g. with oral azacytidine or midostaurin, or ongoing low intensity therapy, e.g. with HMA, venetoclax etc. is permitted, can be applied throughout the vaccination and continued after study treatment according to the treating physician's decision. |
Multi-peptide vaccine cocktail comprising 9 different immunopeptidome-defined mutated and non-mutated AML/ leukemia stem and progenitor cell (LSC)-associated HLA class I and HLA class II peptides. The vaccine cocktail is synthesized and formulated in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
immunogenicity
Délai: Visit 1( Day 0); Visit 2 (Day 42); End of Treatment (Day 70); Follow-Up (Day160); Follow-Up 1(Day 188); Follow-Up 2 (Day 250)
|
Blood will be taken before peptide vaccination and during vaccination phase and follow-ups at each visit IFN-gamma ELISPOT Counts Percentage of patients with induction of an AML-VAC-XS15-specific specific T-cell response until End of study visit (EOS) compared to baseline as determined by IFNγ ELISPOT. |
Visit 1( Day 0); Visit 2 (Day 42); End of Treatment (Day 70); Follow-Up (Day160); Follow-Up 1(Day 188); Follow-Up 2 (Day 250)
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- AML-VAC-XS15-01
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .